An mRNA cancer vaccine developed by Moderna and Merck in combination with a widely used immunotherapy cut the risk of death or recurrence of melanoma by 42% and disease spread by 38%, according to data from a large trial, potentially paving the way for a new era of personalized treatment.
Log in or sign up to comment.